Quest Diagnostics Hits New 52-Week High at $191.45, Surges 34.71%

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 191.45 on September 30, 2025. This achievement underscores the company's strong performance in the market, particularly as it has recorded a remarkable 34.71% increase over the past year, significantly outpacing the S&P 500's performance of 16.09%.
As a mid-cap company in the miscellaneous industry, Quest Diagnostics boasts a market capitalization of USD 29,720 million. The stock's price-to-earnings (P/E) ratio stands at 28.00, indicating a solid valuation relative to its earnings. Additionally, the company offers an impressive dividend yield of 87.16%, which reflects its commitment to returning value to shareholders.

Financially, Quest Diagnostics maintains a debt-to-equity ratio of 0.76, suggesting a balanced approach to leveraging, while its return on equity is a robust 14.78%. The price-to-book ratio is recorded at 4.11, further illustrating the company's market positioning. Overall, this new high marks a notable achievement for Quest Diagnostics in a competitive landscape.